F2GFree to Go (mobile phone package)
References in periodicals archive ?
It is understood that the company transferred all of its assets and employees on or around April 1, 2014, to Floors to Go and the business is being traded by F2G Retail Sales.
Our proposed reversible 4-bit squarer design has 4 F2G gates for generating the necessary fan-out inputs in the first stage.
Ian Nicholson, chief executive of F2G, said, 'Following our successful USD60m financing, I am delighted to welcome Ralf to the F2G team.
F2G Ltd is one of only a small number of companies who have been accepted into this programme and will seek initial approval for F901318, a novel IV and oral, systemic antifungal targeted at Invasive Aspergillosis on the basis of a Phase IIb randomised controlled clinical trial.
Jim Laird, director of Clyde Carpet and Flooring, was appointed a director of F2G Retail Sales on September 1.
F901318 is being developed by F2G to treat invasive aspergillosis and other life-threatening fungal infections and is of a novel class of antifungals acting against a new cellular target.
Eccles-based F2G works towards the development of treatments for fungal lung infections which can prove fatal for patients suffering from weak immunity.
com)-- F2G Ltd, a privately-held antifungal drug discovery and development company and The University of Manchester, today announced the commencement of a 6.
com)-- F2G Ltd, the UK-based antifungal drug discovery and development company, today announced the appointment of Ian Nicholson to the position of CEO and to the Board of Directors.
DBV-Technologies, deCODE chemistry & biostructures, DIREVO Biotech AG, Emergent BioSolutions, ENKAM Pharmaceuticals A/S, Euroscreen SA, EUSA Pharma, Evotec, F2G Limited, Health Protection Agency, ICHOR Medical Systems, Indevus Pharmaceuticals, Inc.
com)-- F2G Limited, the UK based antifungal drug discovery and development company, today announced the appointment of Dr Michael R.
Colby Pharmaceutical Company, Cylene Pharmaceuticals, Dimera Incorporated, DNage, Epeius Biotechnologies Corporation, F2G Limited, Fibrex Medical Inc.